The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Fixed-duration epcoritamab in older patients with newly diagnosed DLBCL and comorbidities
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, presents the results of the EPCORE DLBCL-3 study (NCT05660967), which evaluated fixed-duration epcoritamab monotherapy in older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and comorbidities. Prof. Vitolo highlights that the findings are promising, noting that this chemotherapy-free approach may be a valuable option for patients who are not eligible for standard chemotherapy regimens. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
